Improving the therapeutic index of adcs targeting metastatic breast cancer
Ended Project Grant Awarded Last action
- Award ID
- W81XWH2110109
- Recipient
-
The Geneva Foundation UEI TR9RX33188T4
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $453,029
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date
- Place of performance
- Tacoma, WA 98402, USA
Award details come from USAspending.gov.
About this award
The Geneva Foundation received a $453,029 Project Grant award from the Department of the Army Medical Command on February 1, 2021 to improve the therapeutic index of antibody drug conjugates targeting metastatic breast cancer. Funded through January 31, 2024 under the Military Medical Research and Development program (CFDA 12.420), this award will support the Foundation's work to transform healthcare and investigate medical solutions for the battlefield by developing more effective targeted cancer therapies with reduced side effects. The Military Medical Research and Development program aims to advance biomedical research that can benefit both military service members and the American public.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Original award | $453,029 |
Quick answers
Who received award W81XWH2110109?
W81XWH2110109 was awarded to The Geneva Foundation by Medical Command (Department of the Army) on February 1, 2021.
How much is award W81XWH2110109 worth?
$453,029 has been obligated on W81XWH2110109.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award